Hexagon Nutrition's first post-IPO call: profit up 56%, eyes 15-20% growth
The clinical nutrition specialist reported ₹37.94 cr net profit on ₹382.63 cr revenue and laid out a branded expansion strategy. No surprises, but the detail reduces the information gap.
— 5 earlier stories on Hexagon Nutrition Ltd. →What's new
- Profit up 56% to ₹37.94 cr on revenue of ₹382.63 cr.
- Management guides 15–20% annual revenue growth with better margins.
- Branded segment (PentaSure, Pedia Gold, Obesigo) key driver; expansion into tier-2/3 cities and e-commerce.
Why this matters
For a micro-cap with limited coverage, the call's granular detail reduces information asymmetry. The 15–20% growth guidance and margin outlook give a clearer medium-term target. But with no new financial surprises, the near-term catalyst is modest.
What we're watching
- Conversion of the order pipeline into revenue: capacity utilization is only 30–50%.
- Branded product uptake in tier-2/3 cities and e-commerce channels.
- Export resilience, especially diversification away from the <20% West Asia exposure.
The full read
Hexagon Nutrition held its maiden earnings call as a listed entity, and the headline numbers were strong: net profit up 56% to ₹37.94 crore on revenue of ₹382.63 crore. But the real value of the call was the fill. Management laid out a clear strategy built on the branded clinical nutrition segment (PentaSure, Pedia Gold, Obesigo), expansion into tier-2/3 cities and e-commerce, and a 15–20% annual revenue growth target with better margins. Export revenue, half the total, remains resilient with less than 20% exposure to West Asia. Capacity utilization at 30–50% leaves room for cost efficiencies as orders convert. The analyst rationale notes no new financial surprises: the FY26 results had already been approved. But for a micro-cap with thin coverage, the depth of disclosure cuts through the information fog. The stock trades at 29x trailing earnings. The call gives a roadmap. Execution against it is now the test.
Questions answered
- How did Hexagon Nutrition perform in FY26?
- Consolidated net profit rose 56% to ₹37.94 crore on revenue of ₹382.63 crore, aided by cost efficiencies and an improving product mix.
- What is the growth strategy going forward?
- Management targets 15–20% annual revenue growth with higher margins, driven by the branded segment (PentaSure, Pedia Gold, Obesigo) and expansion into tier-2/3 cities and e-commerce.
- What is the export exposure and geopolitical risk?
- Exports contribute half of total revenue, with less than 20% exposure to West Asia. Management described the export business as resilient with minimal geopolitical impact.
- What is the current capacity utilization?
- Capacity utilization stands at 30–50%. Management expects it to improve as the order pipeline converts, providing scale benefits.
- Does the concall change the investment case?
- The call reduces information asymmetry with detailed segment data and explicit guidance, but the FY26 numbers were already known. The stock trades at a P/E of 29.0. Execution against the growth roadmap is now the key variable.
Hexagon Nutrition Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on HEXAGON →- 17 Jul 2026 · 5:15 PM IST Hexagon Nutrition's first post-IPO call: profit up 56%, eyes 15-20% growth
- 11d ago Hexagon Nutrition directors quit after selling all IPO shares
- 17d ago Hexagon Nutrition board approves FY26 audited results, reappoints auditors
- 18d ago Hexagon Nutrition board signs off on FY26 numbers, no surprises
- 18d ago Hexagon Nutrition posts 42% profit jump in first post-listing year